Owners, management and financials
CVR: 29526346
Secondary names: MC2 Biotek A/S
Previous names: BIOTECH AF 4. MAJ 2006 ApS, MC2 BIOTEK ApS, MC2 Therapeutics ApS
DKK 22,248,504
Gross profit
Net result: DKK -7,816,954
Alsmark Invest II ApS (33,33-49,99%), MC2 HOLDING ApS (15-19,99%)
1 more
CVR · view owners
Trine Ahlgreen
Board: Mads Jørgen Nøhr Clausen (chair) and 3 members
CVR · view management
Active
Founded 4 May 2006
CVR · view overview
10 employees
CVR · 2018
Director role ended: Jesper Jørn Lange
CVR · 26/05/2025
View the full event history
MC2 Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2006. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named MC2 Therapeutics ApS and MC2 BIOTEK ApS. The management consists of Trine Ahlgreen. The board consists of Mads Jørgen Nøhr Clausen (chair), Anders Dahlgaard Hove, John Sørensen Haurum and Tomas Dahl Mikkelsen. The company is owned by Alsmark Invest II ApS, MC2 HOLDING ApS and Selskabet af 4. april 2023 ApS. The company has 10 employees (2018). In 2025, the company reported a gross profit of DKK 22,248,504 and a net result of DKK -7,816,954 compared with DKK -53,006,931 the year before. Equity in the 2025 report amounted to DKK -224,478,927.
Source: annual report 2025, Danish Business Authority
The financial health of MC2 Therapeutics A/S shows a concerning trend, with consistent losses over the past five years, culminating in a profit loss of -7,816,954 DKK in 2025. Gross profit has fluctuated slightly, peaking at 27,734,440 DKK in 2021 but declining to 22,248,504 DKK by 2025. The company's equity position remains weak, with negative equity reaching -224,478,927 DKK, indicating potential challenges in sustaining operations without external funding. As a player in the pharmaceutical manufacturing sector, the company's inability to generate revenue raises significant concerns about its long-term viability and competitive position in the industry.
AI-generated summary · Generated 15/08/2026
Selskabets formål er at udøve innovations-, forsknings- og udviklingsaktivitet indenfor medicinal- og sundheds-branchen, og at drive handelsvirksomhed dermed, samt al virksomhed, som efter bestyrelsens skøn har forbindelse hermed, herunder udvikling, køb og salg af immaterielle rettigheder eller medicinske produkter samt at besidde ejerandele i virksomheder, som udøver lignende aktiviteter.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 22.2 mio. | -7.8 mio. | 56.4 mio. | -224.5 mio. | 20 | |
| 202401/01/2024 – 31/12/2024 | 24.5 mio. | -53 mio. | 64.4 mio. | -218.4 mio. | 16 | |
| 202301/01/2023 – 31/12/2023 | 26.4 mio. | -41.9 mio. | 30.6 mio. | -164.5 mio. | 29 | |
| 202201/01/2022 – 31/12/2022 | 25 mio. | -101.3 mio. | 38.6 mio. | -122.6 mio. | 30 | |
| 202101/01/2021 – 31/12/2021 | 27.7 mio. | -25.2 mio. | 51.6 mio. | -21.1 mio. | 19 | |
| 202001/01/2020 – 31/12/2020 | 15.9 mio. | -86.9 mio. | 36.1 mio. | 13.9 mio. | - | |
| 201901/01/2019 – 31/12/2019 | 13.7 mio. | -81.4 mio. | 105.7 mio. | 65.8 mio. | 11 | |
| 201801/01/2018 – 31/12/2018 | 13.3 mio. | -110.1 mio. | 74.4 mio. | 62.3 mio. | 10 | |
| 201701/01/2017 – 31/12/2017 | 10.3 mio. | -79.1 mio. | 47.2 mio. | 30.9 mio. | 8 | |
| 201601/01/2016 – 31/12/2016 | 6.8 mio. | -40.1 mio. | 78.6 mio. | 54.4 mio. | 5 | |
| 201501/01/2015 – 31/12/2015 | 5.4 mio. | -24.5 mio. | 49.1 mio. | 43.4 mio. | 4 | |
| 201401/01/2014 – 31/12/2014 | 5.6 mio. | -19.8 mio. | 41.1 mio. | 35.4 mio. | 4 | |
| 201301/01/2013 – 31/12/2013 | 3.5 mio. | -25 mio. | 17.2 mio. | 15.9 mio. | 3 | |
| 201201/01/2012 – 31/12/2012 | 5.2 mio. | -31.3 mio. | 6.8 mio. | -288.9 mio. | 4 |
Compared to 128 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringThe CVR number of MC2 Therapeutics A/S is 29526346.
MC2 Therapeutics A/S is owned by Alsmark Invest II ApS, MC2 HOLDING ApS and Selskabet af 4. april 2023 ApS.
The management of MC2 Therapeutics A/S consists of Trine Ahlgreen.
The board of MC2 Therapeutics A/S consists of Mads Jørgen Nøhr Clausen, Anders Dahlgaard Hove and John Sørensen Haurum, with Mads Jørgen Nøhr Clausen as chair.
In 2025, MC2 Therapeutics A/S reported a gross profit of DKK 22,248,504.
MC2 Therapeutics A/S had 10 employees in 2018 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
Contact info changed: new phone: 53514153 (September 11, 2026).
As of September 1, 2026, Cedra Godkendt Revisionsaktieselskab has been appointed auditor of MC2 Therapeutics A/S.
As of September 1, 2026, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of MC2 Therapeutics A/S.
MC2 Therapeutics A/S has published its annual report for 2025. Gross profit came to DKK 22,248,504, and the net result was DKK -7,816,954.
Contact info changed: new phone: 53514153 (June 3, 2026).
MC2 Therapeutics A/S has published its annual report for 2024. Gross profit came to DKK 24,493,422, and the net result was DKK -53,006,931.
As of May 26, 2025, Trine Ahlgreen is registered as director of MC2 Therapeutics A/S.
As of May 26, 2025, Jesper Jørn Lange has stepped down as director of MC2 Therapeutics A/S.
MC2 Therapeutics A/S has published its annual report for 2023. Gross profit came to DKK 26,355,182, and the net result was DKK -41,851,166.
As of December 27, 2023, Alsmark Invest II ApS is registered as an owner of MC2 Therapeutics A/S with an ownership share of 33%.
As of October 26, 2023, John Sørensen Haurum has joined the board of directors of MC2 Therapeutics A/S.
MC2 Therapeutics A/S has published its annual report for 2022. Gross profit came to DKK 25,008,167, and the net result was DKK -101,331,259.
As of July 11, 2023, Selskabet af 4. april 2023 ApS is registered as an owner of MC2 Therapeutics A/S with an ownership share of 33%.
As of January 24, 2023, Tomas Dahl Mikkelsen has joined the board of directors of MC2 Therapeutics A/S.
As of January 24, 2023, Jesper Jørn Lange has left the board of directors of MC2 Therapeutics A/S.
As of November 8, 2022, Mette Vagner Johannesen has left the board of directors of MC2 Therapeutics A/S.
MC2 Therapeutics A/S has published its annual report for 2021. Gross profit came to DKK 27,734,440, and the net result was DKK -25,222,958.
MC2 Therapeutics A/S has published its annual report for 2020. Gross profit came to DKK 15,938,167, and the net result was DKK -86,940,654.
As of September 14, 2020, Paul Louis Berns has left the board of directors of MC2 Therapeutics A/S.
MC2 Therapeutics A/S has published its annual report for 2019. Gross profit came to DKK 13,678,382, and the net result was DKK -81,401,184.
MC2 Therapeutics A/S has published its annual report for 2018. Gross profit came to DKK 13,340,000, and the net result was DKK -110,067,000.
As of June 18, 2018, MC2 HOLDING ApS is registered as an owner of MC2 Therapeutics A/S with an ownership share of 15%.
MC2 Therapeutics A/S has published its annual report for 2017. Gross profit came to DKK 10,252,025, and the net result was DKK -79,128,188.
As of June 20, 2017, Jesper Jørn Lange has joined the board of directors of MC2 Therapeutics A/S.
As of June 20, 2017, Mette Vagner Johannesen has joined the board of directors of MC2 Therapeutics A/S.
As of June 20, 2017, Mads Jørgen Nøhr Clausen has joined the board of directors of MC2 Therapeutics A/S.
As of June 20, 2017, Anders Dahlgaard Hove has joined the board of directors of MC2 Therapeutics A/S.
As of June 20, 2017, Paul Louis Berns has joined the board of directors of MC2 Therapeutics A/S.
On June 20, 2017, the company changed its name from MC2 Therapeutics ApS to MC2 Therapeutics A/S.
MC2 Therapeutics A/S has published its annual report for 2016. Gross profit came to DKK 6,841,876, and the net result was DKK -40,139,989.
On December 1, 2016, the company changed its name from MC2 BIOTEK ApS to MC2 Therapeutics ApS.
MC2 Therapeutics A/S has published its annual report for 2015. Gross profit came to DKK 5,411,435, and the net result was DKK -24,452,032.
MC2 Therapeutics A/S has published its annual report for 2014. Gross profit came to DKK 5,586,065, and the net result was DKK -19,839,747.
MC2 Therapeutics A/S has published its annual report for 2013. Gross profit came to DKK 3,532,206, and the net result was DKK -25,006,950.
MC2 Therapeutics A/S has published its annual report for 2012. Gross profit came to DKK 5,245,429, and the net result was DKK -31,328,487.
As of October 13, 2011, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of MC2 Therapeutics A/S.
As of October 13, 2011, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has stepped down as auditor of MC2 Therapeutics A/S.
As of November 27, 2006, Jesper Jørn Lange is registered as director of MC2 Therapeutics A/S.
As of November 27, 2006, Anette Merete Nøhr Clausen has stepped down as director of MC2 Therapeutics A/S.
On October 12, 2006, the company changed its name from BIOTECH AF 4. MAJ 2006 ApS to MC2 BIOTEK ApS.
As of September 19, 2006, Anette Merete Nøhr Clausen is registered as director of MC2 Therapeutics A/S.
As of September 19, 2006, Steen Sindet-Pedersen has stepped down as director of MC2 Therapeutics A/S.
As of May 4, 2006, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has been appointed auditor of MC2 Therapeutics A/S.
As of May 4, 2006, Steen Sindet-Pedersen is registered as director of MC2 Therapeutics A/S.
MC2 Therapeutics A/S was founded on May 4, 2006.
Companies in the same industry and area
CVR 37728403
CVR 40279865
CVR 34623562
CVR 38445928
CVR 63717916
